Company news
Nkarta, Inc. (NASDAQ:NKTX) news
Nkarta, Inc. news releases on 6ix. Latest, Jan 9, 2023: Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer
Press releases — page 2
Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer
January 8, 2023
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
December 4, 2022
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program
December 1, 2022
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
November 8, 2022
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting
November 6, 2022
Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights
August 10, 2022
Nkarta Announces Key Senior Leadership Team Appointments
July 24, 2022
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development
May 15, 2022
Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights
May 11, 2022
Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares
April 27, 2022
Nkarta Announces Proposed Public Offering of Common Stock
April 24, 2022
Nkarta Announces Pricing of Upsized Public Offering of Common Stock
April 24, 2022
Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
April 24, 2022
Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates
April 21, 2022
Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at AACR Annual Meeting 2022
April 7, 2022
Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors
March 28, 2022
Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
March 16, 2022
Nkarta to Present Preclinical Data from Engineered NK Cell Platform at the American Association for Cancer Research 2022 Annual Meeting
March 7, 2022
Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AML
December 15, 2021
Nkarta Presents NKX019 Trial in Progress Poster at the 2021 ASH Annual Meeting and Exposition
December 12, 2021
Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting
November 11, 2021
Nkarta Reports Third Quarter 2021 Financial Results and Business Update
November 9, 2021
Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs
October 6, 2021
Nkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting
September 30, 2021
Nkarta Reports Second Quarter 2021 Financial Results and Business Progress
August 11, 2021
Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters
July 13, 2021
Nkarta to Present at Upcoming Investor Conference
June 15, 2021
Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term
June 13, 2021
Nkarta Announces June 2021 Investor Conference Schedule
May 24, 2021
Nkarta Reports First Quarter 2021 Financial Results and Business Progress
May 12, 2021
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
May 5, 2021
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
April 27, 2021
Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress
March 24, 2021
Nkarta Announces February and March 2021 Investor Conference Schedule
February 16, 2021
Nkarta Reports Third Quarter 2020 Financial Results
November 11, 2020
Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101
November 11, 2020
Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer
November 8, 2020
Nkarta Announces November & December 2020 Investor Conference Schedule
November 4, 2020
Nkarta Announces Leadership Changes
October 4, 2020
Nkarta Announces October 2020 Investor Conference Schedule
September 28, 2020
Nkarta Announces September 2020 Virtual Investor Conference Schedule
September 7, 2020
Nkarta Reports Second Quarter 2020 Financial Results
August 19, 2020
Nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares
July 13, 2020